Cynosure Group LLC Decreases Position in Chemed Co. (NYSE:CHE)

Cynosure Group LLC trimmed its holdings in shares of Chemed Co. (NYSE:CHE) by 12.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 616 shares of the company’s stock after selling 86 shares during the quarter. Cynosure Group LLC’s holdings in Chemed were worth $370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its stake in Chemed by 105.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 63,733 shares of the company’s stock valued at $40,913,000 after purchasing an additional 32,752 shares in the last quarter. Cetera Advisors LLC acquired a new stake in shares of Chemed during the first quarter worth about $267,000. DekaBank Deutsche Girozentrale boosted its position in Chemed by 34.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 154,579 shares of the company’s stock valued at $98,516,000 after buying an additional 39,633 shares during the last quarter. Park Place Capital Corp increased its holdings in Chemed by 170.0% in the 2nd quarter. Park Place Capital Corp now owns 1,080 shares of the company’s stock worth $586,000 after buying an additional 680 shares during the period. Finally, GAMMA Investing LLC raised its position in Chemed by 34.4% during the 2nd quarter. GAMMA Investing LLC now owns 86 shares of the company’s stock worth $47,000 after buying an additional 22 shares during the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.

Chemed Trading Down 0.4 %

Chemed stock opened at $571.31 on Friday. The firm has a market cap of $8.60 billion, a PE ratio of 28.87, a P/E/G ratio of 2.43 and a beta of 0.46. The stock’s 50 day simple moving average is $578.74 and its two-hundred day simple moving average is $565.02. Chemed Co. has a 12 month low of $523.33 and a 12 month high of $654.62.

Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, October 29th. The company reported $5.64 EPS for the quarter, missing the consensus estimate of $5.76 by ($0.12). The firm had revenue of $606.18 million for the quarter, compared to analyst estimates of $612.22 million. Chemed had a net margin of 12.69% and a return on equity of 27.86%. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.32 EPS. On average, equities research analysts forecast that Chemed Co. will post 21.43 EPS for the current year.

Chemed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Monday, November 18th will be given a dividend of $0.50 per share. The ex-dividend date is Monday, November 18th. This represents a $2.00 dividend on an annualized basis and a yield of 0.35%. Chemed’s dividend payout ratio is currently 10.11%.

Insider Buying and Selling at Chemed

In other Chemed news, EVP Nicholas Michael Westfall sold 1,713 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $569.35, for a total transaction of $975,296.55. Following the transaction, the executive vice president now directly owns 6,109 shares of the company’s stock, valued at $3,478,159.15. This trade represents a 21.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director George J. Walsh III sold 400 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $597.47, for a total transaction of $238,988.00. Following the sale, the director now directly owns 3,046 shares of the company’s stock, valued at $1,819,893.62. This represents a 11.61 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,113 shares of company stock valued at $3,557,445. Company insiders own 3.32% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. StockNews.com lowered shares of Chemed from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Royal Bank of Canada cut their price target on Chemed from $697.00 to $633.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.